Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity

Yoon‐Suk Kang, Simone Cavalcante Silva, Kenny Smith, Keiichi Sumida, Yuhan Wang, Lucius Chiaraviglio, Ramachandra Reddy Donthiri, Alhanouf Z. Aljahdali, James E. Kirby, George A. O’DohertyMolecules 2025 · DOI

TL;DR

This paper explores modifications to the antibiotic fusidic acid to broaden its activity spectrum, particularly against Gram-negative bacteria. While side-chain and C-ring modifications were largely unsuccessful, certain A-ring ester derivatives showed promise, suggesting potential for fusidic acid prodrugs and future development of novel antibiotics.

What Problem Does This Paper Address?

The rise of antibiotic resistance is a critical global health challenge, necessitating the development of new antimicrobial agents. Fusidic acid is a potent antibiotic effective against Gram-positive bacteria like Staphylococcus aureus (including MRSA). However, its efficacy against Gram-negative bacteria is severely limited due to its inability to effectively penetrate their outer membrane and reach its intracellular target, the ribosome-associated protein elongation factor G (EF-G). This paper aims to address this limitation by exploring the structure-activity relationship (SAR) of fusidic acid, specifically investigating whether modifications to its scaffold can enhance its activity against Gram-negative pathogens and improve its overall pharmacological properties.

Methods

The researchers employed an "activity-guided synthetic strategy." This involved synthesizing various derivatives of fusidic acid and then testing their antibacterial activity. The key modification sites explored were:

  • Side-chain carboxylic acid: Esterification was performed using methyl, para-methoxybenzyl, and 2-pyridylmethyl esters.
  • A-ring alcohol: Oxidation to a ketone and subsequent conversion to an oxime were investigated. Esterification with aromatic carboxylic acids (phenyl, pyridyl, pyrazinyl, and oxazolyl) was also carried out.
  • C-ring alcohol: Oxidation to a ketone and conversion to an oxime were explored.

Antibacterial activity was assessed using minimum inhibitory concentration (MIC) assays against Staphylococcus aureus and three strains of Escherichia coli (wild-type, ∆tolC mutant, and lptD4213 mutant). The ∆tolC and lptD4213 mutants were chosen for their increased outer membrane permeability, aiming to overcome the penetration barrier. To understand the mechanism of action, in vitro transcription-translation assays using E. coli S30 ribosome extracts were performed to determine the inhibitory concentration (IC50) of the compounds on protein synthesis.

Datasets

Not discussed in the paper. The study utilized commercially available bacterial strains for testing: Staphylococcus aureus ATCC 25923, E. coli K-12 BW25113, E. coli K-12 JW5503-KanS ∆tolC, and E. coli K-12 RFM795 lptD4213.

Key Insights and Ideas

  • Targeting Gram-negatives is a major hurdle: The inherent difficulty in penetrating the Gram-negative outer membrane is the primary barrier to fusidic acid's broader application.
  • Side-chain esterification is a dead end: Modifying the carboxylic acid side chain with various esters completely abolished antibacterial activity, highlighting the importance of this functional group for interaction with the target or for cellular uptake.
  • A-ring modifications offer a glimmer of hope: While C-ring modifications (oxidation and oxime formation) were detrimental to activity, modifications at the A-ring alcohol, particularly esterification with aromatic carboxylic acids, retained some activity against Gram-positive bacteria and provided valuable SAR data.
  • Prodrug potential: The observation that certain A-ring ester derivatives (e.g., the pyrazine-2-carboxylate ester, 5e) showed better antibacterial activity than predicted by their in vitro translation inhibition suggested a potential prodrug mechanism. This implies that the ester might be hydrolyzed in vivo to release active fusidic acid, potentially with improved pharmacokinetic properties or cellular uptake.
  • Efflux pumps are still a factor: The activity observed in the ∆tolC mutant but not in the wild-type E. coli for some derivatives suggests that efflux pump mechanisms, common in Gram-negative bacteria, can still limit the intracellular concentration of these modified compounds.

Key Results

  • Side-chain esters (2a-c): All were inactive against S. aureus and E. coli.
  • A-ring oxidation/oxime (3a/b, 4a/b): The A-ring mono-ketone (3a) and oxime (3b) retained modest activity against S. aureus (MICs of 8 µM and 16 µM, respectively), while C-ring modifications (4a/b) were detrimental.
  • A-ring aromatic esters (5a-f):
    • Against S. aureus, compounds 5a (benzoate) and 5f (oxazole) showed moderate activity (MICs of 2-4 µM and 16 µM, respectively).
  • Compound 5e (pyrazine-2-carboxylate) exhibited the most promising activity against S. aureus with an MIC of 0.5 µM.
  • None of the A-ring ester derivatives showed significant activity against wild-type E. coli. Some activity was observed in the ∆tolC mutant, but not in the lptD4213 mutant.
  • In vitro translation assays: Generally, compounds that showed antibacterial activity also inhibited ribosome translocation, consistent with fusidic acid's known mechanism. However, compound 5e's antibacterial potency was significantly higher than its in vitro translation inhibitory activity, supporting the prodrug hypothesis.

Limitations and Future Work

  • Limited Gram-negative activity: Despite exploring modifications, none of the synthesized compounds achieved significant activity against wild-type Gram-negative bacteria. The penetration barrier remains a major challenge.
  • Prodrug hypothesis needs further validation: While the data for compound 5e is suggestive, further studies are needed to confirm the prodrug mechanism and its contribution to antibacterial activity.
  • Future Work: The authors suggest that further investigation into A-ring ester derivatives as potential prodrugs is warranted. Exploring other modifications at the A-ring alcohol and investigating strategies to improve Gram-negative cell penetration are also promising avenues for future research. The goal is to develop fusidic acid derivatives with an expanded spectrum of activity and improved pharmacological properties.

Summary updated

Abstract

Fusidic acid is a translation inhibitor with activity against major Gram-positive bacterial pathogens such as <i>S. aureus</i>. However, its activity against Gram-negatives is poor based on an inability to access its cytoplasmic target in these organisms. Opportunities for functionalization of the fusidic acid scaffold to enhance activity against Gram-negative pathogens have not been explored. Using an activity-guided synthetic strategy, the tolerance of the tetracyclic natural product to derivatization at the A- and C-rings and its carboxylic acid side chain was explored with the goal of enhancing its activity spectrum and pharmacological properties. All side-chain carboxylic acid esters were inactive. Oxidation of the C-ring alcohol and oxime were not tolerated either. A number of esters of the A-ring alcohol retained modest activity against Gram-positive bacteria and were informative for future activity-guided studies. For the A-ring esters, differences in antibacterial activity relative to inhibitory activity in a ribosome in vitro translation assay suggested the possibility of a pro-druglike effect for the fusidic acid pyrazine-2-carboxylate. This study furthers the understanding of the activity of the fusidic acid scaffold against Gram-positive bacteria. These results suggest promise for future modification of the A-ring alcohol of fusidic acid in the advancement of its antibiotic properties.
BibTeX
@inproceedings{kang2025exploration,
  author = {Yoon‐Suk Kang and Simone Cavalcante Silva and Kenny Smith and Keiichi Sumida and Yuhan Wang and Lucius Chiaraviglio and Ramachandra Reddy Donthiri and Alhanouf Z. Aljahdali and James E. Kirby and George A. O’Doherty},
  title = {{Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity}},
  booktitle = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30030465},
}
Figure